<DOC>
	<DOCNO>NCT00587015</DOCNO>
	<brief_summary>A dose-escalation study estimate maximum tolerate dose ( MTD ) CAT-8015 safely administer patient .</brief_summary>
	<brief_title>A Phase I , Multicenter , Dose Escalation Study CAT-8015 Patients With Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description>To estimate maximum tolerate dose ( MTD ) , define high dose safely administer patient , establish safe dose , base MTD , subsequent clinical testing .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Subjects must meet follow criterion eligible participate study : Confirmed diagnosis Bcell nonHodgkin 's lymphoma Measurable disease Evidence CD22positive malignancy follow criterion , &gt; 30 % malignant cell disease site CD22+ FACS analysis , &gt; 15 % malignant cell disease site must react antiCD22 immunohistochemistry Disease characteristic : Patients indolent subtypes CD22+ Bcell non Hodgkin 's lymphoma , include , limited mantle cell lymphoma , follicular lymphoma Waldenström 's macroglobulinemia , eligible stage IIIIV . stage IIIIV . Patients must fail least two course prior standard chemotherapy and/or biologic therapy ( e.g . Rituxan ) . Patients progressive mantle cell lymphoma may eligible fail one prior standard therapeutic regimen . ECOG performance status 02 Patients cancer meet eligibility criterion le 5 year disease free survival consider casebycase basis Life expectancy le 6 month , assess principal investigator Must able understand sign inform consent Must least 18 year old Female male patient must agree use approve method contraception study Subjects meeting follow criterion eligible participation study : History allogeneic bone marrow transplant Documented ongoing central nervous system involvement malignant disease ( history CNS involvement exclusion criterion ) Pregnant breastfeed female HIV positive serology ( due increase risk severe infection unknown interaction CAT8015 antiretroviral drug ) Hepatitis B surface antigen positive Uncontrolled , symptomatic , intercurrent illness include limited : infection require systemic antibiotic , congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness , social situation would limit compliance study requirement Patients whose plasma contain either significant level antibody CAT8015 measure ELISA , antibody neutralizes bind CAT8015 CD22 measure competition ELISA . Hepatic function Serum transaminases ( either ALT AST ) bilirubin : ≥ Grade 2 , unless bilirubin due Gilbert 's disease Renal function : serum creatinine clearance ≤ 60mL/min estimate CockroftGault formula Hematologic function : The ANC &lt; 1000/cmm , platelet count &lt; 50,000/cmm , cytopenia judge investigator due underlying disease ( i.e . potentially reversible antineoplastic therapy ) . A patient exclude pancytopenia ≥ Grade 3 , erythropoietin dependence , due disease , base result bone marrow study Baseline coagulopathy great equal Grade 3 unless due anticoagulant therapy . Pulmonary function : Patients &lt; 50 % predict forced expiratory volume ( FEV1 ) &lt; 50 % predict diffusing capacity carbon monoxide ( DLCO ) , correct hemoglobin concentration alveolar volume . Note : Patients prior history pulmonary illness require PFTs . FEV1 assess bronchodilator therapy . Recent prior therapy : Cytotoxic chemotherapy , corticosteroid ( except stable dos prednisone ) , whole body electron beam radiation therapy , hormonal , biologic standard investigational therapy malignancy 3 week prior entry trial Less equal 1 month prior monoclonal antibody therapy ( i.e . rituximab ) Patients receive receive radiation therapy le 3 week prior study entry exclude providing volume bone marrow treat less 10 % also patient measurable disease outside radiation port Any history prior pseudomonasexotoxin immunotoxin ( PE ) administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>